Roche's CAPP buy helps cancer drug development
This article was originally published in Scrip
Executive Summary
A new acquisition by Roche in the field of liquid biopsy stands to bolster the company's anticancer R&D. Roche has expanded its presence in the space by buying CAPP Medical, a Palo Alto, California-based company that has developed technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in the blood.